why choose us

First received: January 29, 2024

Clinical Trial: A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Healthy

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Participant- and Investigator-blinded, Randomized, Single-dose Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants

Brief Summary: The main purpose of this study is to determine the tolerability and side effects related to lebrikizumab comparing with placebo given as a single dose administered under the skin to healthy Chinese participants.The study will also assess how fast lebrikizumab gets into the blood stream and how long the body takes to get rid of it.Each enrolled participant will receive a single dose of either Lebrikizumab or placebo.For each participant, the total duration of the study will be approximately up to 21 weeks,…

Read more